Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | DRD5 | P21918 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 5/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.40 |
| ▸ | HRH1 | P35367 | 3/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | HRH2 | P25021 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4670353 | 0.86 | FFAR1 (0.46) | HTR7CYP2D6ADRA2AADRA2BCHRM3 | |
| SCHEMBL7688533 | 0.84 | DRD3 (0.44) | DRD1DRD2CYP2D6CHRM2CHRM1 | |
| SCHEMBL5268171 | 0.82 | FFAR1 (0.48) | HTR7CYP2D6ADRA2AADRA2BCYP2C19 | |
| SCHEMBL30786891 | 0.81 | FFAR1 (0.43) | HTR7CYP2D6CHRM3CYP2C19CYP3A4 | |
| SCHEMBL4199005 | 0.81 | ADRB2 (0.48) | ADRB2ADRB1DRD1DRD2DRD4 | |
| SCHEMBL4669318 | 0.80 | FFAR1 (0.45) | HTR7CHRM3FFAR1FFAR4ALDH1A1 | |
| SCHEMBL15845873 | 0.75 | TAAR1 (0.59) | ADRB2ADRB1DRD1DRD2DRD4 | |
| SCHEMBL6771225 | 0.73 | CYP1A2 (0.47) | HTR7CYP2D6SLC6A2HTR2ASLC6A4 | |
| SCHEMBL13176996 | 0.73 | FFAR1 (0.47) | HTR7CYP2D6CYP2C19CYP3A4FFAR1 | |
| SCHEMBL2792229 | 0.73 | ADRA1A (0.44) | ADRB2ADRB1DRD1DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703823-B2 | Methods for treatment of migraine and symptoms thereof | SALEHANI FOAD (US) | 2014-04-22 | — | — | US | disclosed |
| US-20090018205-A1 | METHODS FOR TREATMENT OF MIGRAINE AND SYMPTOMS THEREOF | SALEHANI FOAD | 2009-01-15 | — | — | US | disclosed |
| US-7449174-B2 | Delivery of analgesics through an inhalation route | ALEXZA PHARMACEUTICALS, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20060251587-A1 | Delivery of analgesics through an inhalation route | ALEXZA PHARMACEUTICALS, INC. (US) | 2006-11-09 | — | — | US | disclosed |
| US-7070762-B2 | Delivery of analgesics through an inhalation route | ALEXZA PHARMACEUTICALS, INC. (US) | 2006-07-04 | — | — | US | disclosed |
| US-7070764-B2 | Delivery of analgesics through an inhalation route | ALEXZA PHARMACEUTICALS, INC. (US) | 2006-07-04 | — | — | US | disclosed |
| US-20050282879-A1 | Methods and composition for treatment of migraine and symptoms thereof | SALEHANI FOAD | 2005-12-22 | — | — | US | disclosed |
| US-6855310-B2 | Aerosol for inhalation therapy, wherein the aerosol comprises particles comprising at least 10 percent by weight of acetaminophen, orphenadrine or tramadol. | ALEXZA MOLECULAR DELIVERY CORPORATION (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040191182-A1 | Delivery of analgesics through an inhalation route | ALEXZA MOLECULAR DELIVERY CORPORATION | 2004-09-30 | — | — | US | disclosed |
| US-20040126329-A1 | Delivery of analgesics through an inhalation route | ALEXZA MOLECULAR DELIVERY CORPORATION | 2004-07-01 | — | — | US | disclosed |
| US-20030017117-A1 | Delivery of analgesics through an inhalation route | ALEXZA PHARMACEUTICALS, INC. | 2003-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282879-A1 | Methods and composition for treatment of migraine and symptoms thereof | HRH3, HRH4, HNMT | ADRB2 347/4885ADRB1 578/4885DRD1 1729/4885 |
| US-20090018205-A1 | METHODS FOR TREATMENT OF MIGRAINE AND SYMPTOMS THEREOF | HNMT, HRH3, HRH4 | ADRB2 459/4885ADRB1 681/4885DRD1 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.